Frontiers in Psychiatry (Apr 2021)
Alexithymia in Patients With Substance Use Disorders and Its Relationship With Psychiatric Comorbidities and Health-Related Quality of Life
- Raul F. Palma-Álvarez,
- Raul F. Palma-Álvarez,
- Raul F. Palma-Álvarez,
- Raul F. Palma-Álvarez,
- Elena Ros-Cucurull,
- Elena Ros-Cucurull,
- Elena Ros-Cucurull,
- Elena Ros-Cucurull,
- Constanza Daigre,
- Constanza Daigre,
- Constanza Daigre,
- Constanza Daigre,
- Marta Perea-Ortueta,
- Marta Perea-Ortueta,
- Pedro Serrano-Pérez,
- Pedro Serrano-Pérez,
- Pedro Serrano-Pérez,
- Nieves Martínez-Luna,
- Anna Salas-Martínez,
- María Robles-Martínez,
- María Robles-Martínez,
- Josep A. Ramos-Quiroga,
- Josep A. Ramos-Quiroga,
- Josep A. Ramos-Quiroga,
- Josep A. Ramos-Quiroga,
- Carlos Roncero,
- Carlos Roncero,
- Lara Grau-López,
- Lara Grau-López,
- Lara Grau-López,
- Lara Grau-López
Affiliations
- Raul F. Palma-Álvarez
- Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Raul F. Palma-Álvarez
- Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
- Raul F. Palma-Álvarez
- Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain
- Raul F. Palma-Álvarez
- Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain
- Elena Ros-Cucurull
- Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Elena Ros-Cucurull
- Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
- Elena Ros-Cucurull
- Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain
- Elena Ros-Cucurull
- Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain
- Constanza Daigre
- Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Constanza Daigre
- Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
- Constanza Daigre
- Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain
- Constanza Daigre
- Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain
- Marta Perea-Ortueta
- Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Marta Perea-Ortueta
- Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain
- Pedro Serrano-Pérez
- Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Pedro Serrano-Pérez
- Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
- Pedro Serrano-Pérez
- Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain
- Nieves Martínez-Luna
- Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Anna Salas-Martínez
- Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- María Robles-Martínez
- Institute of Neuropsychiatry and Addictions (INAD), Parc de Salut Mar, Barcelona, Spain
- María Robles-Martínez
- Hospital del Mar Institute for Biomedical Research (IMIM), Barcelona, Spain
- Josep A. Ramos-Quiroga
- Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Josep A. Ramos-Quiroga
- Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
- Josep A. Ramos-Quiroga
- Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain
- Josep A. Ramos-Quiroga
- Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain
- Carlos Roncero
- Psychiatry Service, University of Salamanca Health Care Complex, Insitute of Biomedicine, Salamanca, Spain
- Carlos Roncero
- Psychiatry Unit, School of Medicine, University of Salamanca, Salamanca, Spain
- Lara Grau-López
- Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Lara Grau-López
- Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
- Lara Grau-López
- Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain
- Lara Grau-López
- Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain
- DOI
- https://doi.org/10.3389/fpsyt.2021.659063
- Journal volume & issue
-
Vol. 12
Abstract
Background: Alexithymia frequently correlates with several psychiatric disorders, including substance use disorder (SUD). However, most studies reporting the associations between alexithymia and psychiatric disorders have been performed in populations without SUD. This research, therefore, evaluates alexithymia in Spanish patients with SUD and the relationship among alexithymia, psychiatric comorbidities, psychological symptoms/traits, SUD variables, and health-related quality of life (HRQoL).Methodology: A cross-sectional study was conducted with 126 Spanish outpatients with SUD (75.4% males; mean age 43.72 ± 14.61 years), correlating their alexithymia levels (using the Toronto Alexithymia Scale 20 [TAS-20]) to their psychiatric comorbidities, psychological symptoms/traits, SUD variables, and HRQoL.Results: Alexithymia was significantly higher in patients who had cannabis use disorder. Higher alexithymia scores were also related to higher levels of depression, anxiety, impulsivity, and lower HRQoL. After multivariate analysis, trait anxiety, impulsivity, and the physical component summary of the HRQoL were found to be independently related to alexithymia.Conclusions: SUD patients with higher alexithymia levels have more frequently psychiatric comorbidities, present specific psychological features, and have worse HRQoL. Hence, it is important to evaluate these factors and offer more accurate psychotherapeutic approaches for this patient population.
Keywords